

Plasma concentrations and subcutaneous adipose tissue mRNA expression of clusterin in obesity and type 2 diabetes mellitus: the effect of short-term hyperinsulinemia, very-low-calorie diet and bariatric surgery

J. KLOUČKOVÁ¹, Z. LACINOVÁ¹, P. KAVÁLKOVÁ¹, P. TRACHTA¹, M. KASALICKÝ², D. HALUZÍKOVÁ^{1,3}, M. MRÁZ¹, M. HALUZÍK^{1,4}

¹Third Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

²Department of Surgery, Second Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic

³Department of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

⁴Institute of Endocrinology, Prague, Czech Republic

Corresponding author:

Prof. Martin Haluzík, MD, DSc., Third Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 1, 128 08 Prague 2, Czech Republic.

Fax: + 420 224919780.

E-mail: mhalu@lf1.cuni.cz

Short title: Clusterin in obesity and T2DM

SUMMARY

Clusterin is a heterodimeric glycoprotein with wide range of functions. To further explore its possible regulatory role in energy homeostasis and in adipose tissue, we measured plasma clusterin and its mRNA expression in subcutaneous adipose tissue (SCAT) of 15 healthy lean women, 15 obese women (OB) and 15 obese women with type 2 diabetes mellitus (T2DM) who underwent a 2-week very low-calorie diet (VLCD), 10 obese women without T2DM who underwent laparoscopic sleeve gastrectomy (LSG) and 8 patients with T2DM, 8 patients with impaired glucose tolerance (IGT) and 8 normoglycemic patients who underwent hyperinsulinemic euglycemic clamp (HEC). VLCD decreased plasma clusterin in OB but not in T2DM patients while LSG and HEC had no effect. Clusterin mRNA expression in SCAT at baseline was increased in OB and T2DM patients compared with controls. Clusterin mRNA expression decreased 6 months after LSG and remained decreased 12 months after LSG. mRNA expression of clusterin was elevated at the end of HEC compared with baseline only in normoglycemic but not in IGT or T2DM patients. In summary, our data suggest a possible local regulatory role for clusterin in the adipose tissue rather than its systemic involvement in the regulation of energy homeostasis.

Key words: Clusterin, Subcutaneous adipose tissue, Obesity, Bariatric surgery, Very-low-calorie diet

INTRODUCTION

Clusterin, also known as apolipoprotein J (ApoJ), sulfated glycoprotein-2 (SGP-2), SP 40,40 and under numerous other names, is a heterodimeric glycoprotein with a molecular weight of 70-80kDa. It was isolated for the first time in 1983 as a protein capable of aggregation of Sertoli cells to clusters (Blaschuk *et al.* 1983, Fritz *et al.* 1983). Clusterin is expressed by most of the tissues and is present also in plasma, breast milk, cerebrospinal fluid and semen (Aronow *et al.* 1993, Choi-Miura *et al.* 1992, Kounnas *et al.* 1995). Clusterin has multiple functions including those in lipid transport, complement inhibition, regulation of sperm maturation, inflammation, cell migration and apoptosis (Jenne *et al.* 1991, Trougakos *et al.* 2002). Its higher levels are associated with Alzheimer dementia, type 2 diabetes mellitus, metabolic syndrome and cardiovascular diseases (Song *et al.* 2012, Trougakos *et al.* 2002). Nevertheless, its main function still remains to be defined. It is possible that clusterin has either multiple different independent functions in the body or it may have some universal regulatory function such as acting as a chaperon protecting cells in different tissues from stress (Humphreys *et al.* 1999).

Approximately 40-60 % of circulating clusterin is bound to apolipoprotein A-I as a part of the high density lipoprotein (HDL) (James *et al.* 1991, Jenne *et al.* 1991); however, it can also be part of low or very low density lipoprotein (LDL, VLDL) (Hoofnagle *et al.* 2010, Pettersson *et al.* 2011). Clusterin also creates binding complexes with leptin which could be part of the HDL or non-lipoprotein part of blood serum (Bajari *et al.* 2003). In *in vitro* studies, clusterin-leptin complex is able to bind to both leptin and LDL receptors (Bajari *et al.* 2003). Therefore, it has been suggested that clusterin could act as a regulator of leptin activity (Bajari *et al.* 2003). Nevertheless, other data do not support such conclusion. For example: Arnold and colleagues (Arnold *et al.* 2011) have shown that in the group of obese adolescents before and after weight reduction only 1 % of serum leptin was bound to clusterin or HDL and that

there were no correlations between serum clusterin and leptin. Poulakou and colleagues (Poulakou *et al.* 2008) even found an inverse relationship between serum clusterin and leptin or HDL, respectively, in patients with coronary heart disease. No clear relationship was identified between BMI and serum clusterin levels (Arnold *et al.* 2011, Kujiraoka *et al.* 2006, Poulakou *et al.* 2008). Nevertheless, weight loss induced both by hypocaloric diet and laparoscopic gastrectomy was found to lower serum clusterin levels in some studies (Arnold *et al.* 2011, Oberbach *et al.* 2011).

Information on the possible role of clusterin in the regulation of adipose tissue function or in the etiopathogenesis of type 2 diabetes mellitus (T2DM) is conflicting. While in some studies patients with T2DM had higher plasma clusterin concentrations which positively correlated with plasma glucose levels (Kujiraoka *et al.* 2006, Trougakos *et al.* 2002), in another study no difference in clusterin levels between healthy and diabetic patients was found (Poulakou *et al.* 2008). T2DM patients had also a lower percentage of clusterin in HDL (Hoofnagle *et al.* 2010) and higher clusterin percentage in LDL particles (Pettersson *et al.* 2011) compared with healthy controls. Considering the possible cardioprotective function of clusterin and HDL, this difference may be among multiple contributors leading to higher cardiovascular risk in T2DM (Hoofnagle *et al.* 2010).

We have identified clusterin by low density Protein Array as one of the proteins being markedly increased in the adipose tissue of obese patients suggesting that it may also have a local regulatory role in adipose tissue and its metabolic changes in obesity. To this end, we measured mRNA expression of clusterin in adipose tissue and its plasma concentrations in obese patients with and without type 2 diabetes mellitus and explored its modulation by different intervention to gain further insight into its possible regulatory role in the adipose tissue.

METHODS

Study subjects and interventions

This paper presents the data from three substudies. Fifteen obese women (OB group) and fifteen obese women with type 2 diabetes mellitus (T2DM group) who underwent a 2-week very low-calorie diet (VLCD) with energy intake 2500kJ per day (600 kcal per day) were included into the first substudy. During the reduction program all patients were hospitalized at the Third Department of Medicine, General University Hospital in Prague.

Ten obese women without T2DM who underwent laparoscopic sleeve gastrectomy (LSG; LSG-OB group) at the Surgical Clinic, Central Military Hospital in Prague were included into the second substudy. The patients were referred to LSG based on the criteria recommended by European Obesity Society (Fried *et al.* 2013).

As a control group for the substudy one and two, fifteen healthy lean women (BMI 20-25kg/m²) were included.

Eight patients with T2DM (H-T2DM group), eight patients with impaired glucose tolerance (H-IGT group) and eight normoglycemic patients (H-NGT group) who underwent euglycemic hyperinsulinemic clamp (HEC) were included into the third substudy. Each group in this substudy consisted of 4 men and 4 women and all patients had BMI between 20 and 35 kg/m². HEC was initiated by continuous insulin infusion with the rate of 2 mIU/kg/min for patients with BMI < 30kg/m² or 80 mIU/m²/min for patients with BMI ≥ 30kg/m². After 5min, the infusion rate was reduced by half and maintained at this level till the end of the test. Plasma glucose levels were measured every 5 minutes throughout the test. To achieve euglycemia, glucose infusion was started 5min after the start of insulin infusion. The glucose infusion rate was adjusted during the test in order to achieve normoglycemia between 150 and 180 min of the test (steady state). As a measure of insulin sensitivity, Insulin Sensitivity Index

($MCR_{glc}/I - ml \cdot kg^{-1} \cdot min^{-1}$ per $\mu IU \cdot ml^{-1}$) was calculated as the metabolic clearance rate for glucose (MCR_{glc} , $ml \cdot kg^{-1} \cdot min^{-1}$) divided by the mean insulin concentration during steady state.

The body weight of all study participants remained stable for at least three months before the enrollment into the study. Written informed consent was signed by all participants before beginning of the study. The study was approved by Human Ethical Review Committee, First Faculty of Medicine and General University Hospital, Prague, Czech Republic and was performed in accordance with the guidelines proposed in the Declaration of Helsinki.

Anthropometric examination, blood and adipose tissue sampling

Control subjects and subjects who underwent HEC were examined only once. Patients included in the reduction program (T2DM and OB group) were examined twice; at baseline and after 2 weeks of VLCD. Obese patients who underwent LSG (LSG-OB group) were examined three times; at baseline (1 week before LSG), 6 and 12 months after surgery.

All subjects were measured and weighted, and their BMI was calculated. Blood samples for biochemical and hormonal measurements were withdrawn after 12 h of overnight fasting. Blood samples were separated by centrifugation for 10 min at 1000 x g within 30 min from blood collection. Serum and plasma samples were subsequently stored in aliquots at -80 °C until further analysis.

Samples of subcutaneous adipose tissue for mRNA expression analysis were obtained from abdominal region by subcutaneous needle aspiration biopsy. All samples were taken from approximately the same location. In HEC substudy, the samples were obtained 30 min before the start of HEC and 30 min after the end of HEC. Approximately 100 mg of adipose tissue was collected to 1 ml of RNA stabilization Reagent (RNAlater, Qiagen, Hilden, Germany) and stored at - 80 °C until further analysis.

Hormonal and biochemical assays

Plasma clusterin levels were measured by a commercial ELISA kit (BioVendor, Brno, Czech Republic). Sensitivity was 0.5 ng/ml, inter- and intraassay variability were <7 % and <9 %, respectively.

Plasma leptin concentrations were measured by a commercial ELISA kit (BioVendor, Brno, Czech Republic) with a sensitivity 0.12 ng/ml. Serum insulin concentrations were measured by commercial RIA kit (Cis Bio International, Gif-sur-Yvette Cedex, France) with a sensitivity 2.0 IU/ml. Serum C-reactive protein (CRP) levels were measured by high sensitive assay (eBioscience, Vienna, Austria) with a sensitivity 3 pg/ml. The intra- and interassay variabilities of all methods were less than 5 % and less than 10 %, respectively.

Biochemical parameters (glucose, glycated hemoglobin, triglycerides, total and HDL cholesterol) were measured and LDL cholesterol was calculated in the Department of Biochemistry of General University Hospital by standard laboratory methods. The homeostasis model assessment index (HOMA-IR) was calculated using the following formula: (fasting serum insulin (mIU/l) × fasting serum glucose (mmol/l))/22.5.

Determination of mRNA expression

Samples of subcutaneous adipose tissue were homogenized on a MagNA Lyser Instrument using MagNA Lyser Green Beads (Roche Diagnostics GmbH, Germany). Total RNA was extracted from the homogenized sample on MagNA Pure instrument using MagNA Pure Compact RNA Isolation (Tissue) kit (Roche Diagnostics GmbH, Germany). The RNA concentration was determined from absorbance at 260 nm and the integrity of RNA was controlled by 260/280 nm absorbance ratio (NanoPhotometer, Implen, Munchen, Germany). Reverse transcription was performed using 0.25 µg of total RNA to synthesize the first strand

cDNA using the random primers as per the instructions of the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA).

Measurements of mRNA expression of clusterin and leptin were performed on an ABI PRISM 7500 instrument (Applied Biosystems, Foster City, CA, USA) using TaqMan® Universal PCR Master Mix, NO AmpErase® UNG and specific TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) and nuclease-free water (Fermentas Life Science, Vilnius, Lithuania). The increase in fluorescence was measured in real time and threshold cycle (CT) values were obtained. To compensate for variations in the amount of RNA used and for the variable efficiency of reverse transcription, the target gene CT number was normalized to the endogenous control gene beta-2-microglobulin and the formula $2^{-\Delta\Delta CT}$ was used to calculate relative mRNA expression. The results are expressed in arbitrary units.

Comparison of the amount of selected proteins in subcutaneous adipose tissue between control, obese and T2DM patients using low density Protein Array

Samples of subcutaneous adipose tissue were sonicated 10 minutes on ice-cold homogenization buffer [150 mM NaCl, 2 mM EDTA, 10 % glycerol, 25 mM benzamidine, 1 mM PMSF, and protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA) in 10 mM Tris-HCl (pH 7.0)]. The homogenate was centrifuged at 3,000 x g for 15 min at 4 °C, the fat cake was then discarded and the homogenate was centrifuged again at 14,000 x g for 20 min at 4 °C. The supernatant was stored in aliquots at -80 °C. Total amount of protein in each sample was assessed using the Bradford method with Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using BSA as a standard.

350 µg of total protein was transferred to each Human Apoptosis Antibody Array (R&D System, Inc., Minneapolis, MN, USA) and array was processed according to the manufacturer instruction.

Detection of membrane antibody binding was evaluated by SuperSignal West Dura Chemiluminescent ECL Substrate (Pierce Biotechnology, Inc., Rockford, IL, USA). Signals were visualized and evaluated on a G:Box iChemi XT Bio instrument (Syngene, Cambridge, U.K.). Results were analyzed and the quantifications of bands were calculated using GeneTools Software (Syngene, Cambridge, U.K.).

For the pilot scan of 35 proteins in adipose tissue, samples from a control subject (age 51 yrs; BMI 23.3 kg/m²), an obese subject without T2DM (age 60 yrs; BMI 50.0 kg/m²) and an obese woman with T2DM before and after VLCD (age 49 yrs; BMI 74.6 kg/m² vs. 69.6 kg/m²) were used.

Statistical analysis

Statistical analysis was performed on SigmaPlot 13.0 software (Systat Software, Inc., San Jose, CA, USA). Prior to analysis, all continuous variables were assessed for normality. Anthropometric, hormonal and biochemical results are expressed as means ± SEM (standard error of the means).

Differences between control group and obese and/or T2DM patients were evaluated using One way ANOVA vs. Control group or Kruskal-Wallis one way analysis of variance on ranks with Multiple comparisons versus Control group (Holm-Sidak method or Dunn's method), as appropriate. Differences between values before and after the reduction program and mRNA expression before and after HEC were evaluated using Paired t-test or Wilcoxon signed rank test, as appropriate. Differences between values before and 6 and 12 months after LSG were evaluated using One way RM ANOVA with Fisher LSD method or its nonparametric version, according to the normality of data. Changes of plasma and serum concentrations during HEC versus baseline were evaluated using Friedman repeated measures analysis of variance on ranks and Multiple comparisons versus Control group (Dunn's method).

To evaluate the associations between plasma clusterin or clusterin mRNA expression and other variables Pearson or Spearman correlation test were used, according to the normality of data. Variables with $p < 0.05$ were further used for the Multiple linear regression analysis using Backward stepwise variable selection method.

Statistical significance for all tests was assigned to p value < 0.05 .

RESULTS

Difference in the amount of selected proteins in subcutaneous adipose tissue between control, obese and T2DM patients using low density Protein Array

For the pilot scan of 35 proteins in adipose tissue, samples of 1 patient in each group were used. As such, it was not possible to evaluate these data statistically.

After correction to positive controls, the detected amount of clusterin in the sample of SCAT from the obese patient was 9.92times higher and from the T2DM patient before VLCD 0.54times and after VLCD 1.36times higher compared with the control subject (



Figure 1).

The influence of VLCD on hormonal and biochemical parameters and mRNA expression in T2DM and OB patients

Clinical, hormonal and metabolic characteristics and mRNA expression of the control group and OB and T2DM patients before and after 2 weeks of VLCD are shown in Table 1. As expected, BMI, body fat, waist circumference, HOMA index, serum insulin, CRP and leptin concentrations were higher in both obese and T2DM group at baseline relative to control subjects. Fasting blood glucose, glycated hemoglobin and triglycerides were higher and HDL cholesterol was lower only in T2DM group relative to control subjects. There were no significant differences between the groups at baseline in the LDL and total cholesterol.

Two weeks of VLCD decreased BMI, waist circumference, HDL and total cholesterol in both obese and T2DM group, decreased body fat, CRP and leptin in obese group only and decreased LDL cholesterol in T2DM group only. Two weeks of VLCD did not influence fasting blood glucose, triglycerides and insulin levels. Relative gene mRNA expression of leptin did not differ between study groups at baseline and was not influenced by VLCD.

Plasma clusterin levels did not differ between OB, T2DM and control groups at baseline. Two weeks of VLCD decreased clusterin in the obese group whereas its levels in T2DM group were not influenced. Clusterin mRNA expression at baseline was higher in both OB and T2DM groups and remained elevated after VLCD. There were no significant differences in clusterin plasma levels and mRNA expression between OB and T2DM groups.

The effect of LSG on hormonal and biochemical parameters and mRNA expression in obese non-diabetic patients

Clinical, hormonal and metabolic characteristics and mRNA expression of the control group and OB patients before and 6 and 12 months after LSG are shown in Table 2.

BMI, body fat, waist circumference, HDL cholesterol, fasting insulin, HOMA index, CRP and leptin concentrations were higher in obese group before laparoscopic sleeve gastrectomy (LSG) compared with control subjects. At baseline, there were no significant differences in glycated hemoglobin, triglycerides, LDL and total cholesterol.

Six months after LSG BMI, body fat, waist circumference, CRP and leptin levels were decreased. All these values remained decreased 12 months after LSG compared with baseline. Triglyceride levels were decreased and HDL cholesterol increased only 12 months after the LSG. Fasting blood glucose, glycated hemoglobin, total cholesterol, fasting insulin and HOMA index were not affected by LSG.

Plasma clusterin levels did not differ between obese and control groups at baseline and were not affected by LSG.

mRNA expression of both leptin and clusterin was higher in obese patients before LSG compared with control group. Clusterin mRNA remained elevated both 6 and 12 months after LSG, whereas leptin mRNA decreased 6 months after LSG to the levels comparable with control group while increasing again 12 months after LSG.

The effect of euglycemic hyperinsulinemic clamp on hormonal and biochemical parameters and mRNA expression in NGT, IGT and T2DM patients

The clinical, hormonal and metabolic characteristics of the patients who underwent hyperinsulinemic euglycemic clamp (HEC) are shown in Table 3. There was no difference

between the genders in basal plasma clusterin in the combined population of all patients (52.3 ± 3.4 ng/ml for males vs. 47.0 ± 3.9 ng/ml for females; $p = 0.322$). Similarly, there were no significant differences between groups in plasma clusterin during HEC (data not shown).

Compared with normoglycemic patients (NGT), the impaired glucose tolerance (IGT) and T2DM group had higher fasting blood glucose and HOMA index and were slightly older. In addition, T2DM group had higher glycated hemoglobin and HOMA index compared with NGT group and reduced HDL cholesterol compared with both NGT and IGT, whereas total cholesterol was lower compared with IGT group. There were no significant differences between groups in basal leptin.

Analogously, no significant differences between groups in the basal mRNA expression of clusterin and leptin could be observed. At the end of HEC, mRNA expression of clusterin was increased compared with baseline in the NGT group but not in the IGT and T2DM groups. mRNA expression of leptin was increased at the end of HEC compared with baseline in the IGT group but not in the NGT and T2DM patients (Table 3).

We did not find any significant relationships between plasma clusterin area under the curve or its mRNA expression and insulin sensitivity index (data not shown).

Relationship of plasma clusterin levels and its mRNA expression in SCAT to other studied parameters

The relationship of plasma clusterin levels and its mRNA expression in SCAT to other studied parameters was calculated in a combined population of healthy controls, OB, IGT and T2DM subjects at baseline and in the combined population consisting only of subjects with normal glucose tolerance (healthy controls and OB subjects at baseline) (Table 4).

Plasma clusterin correlated positively with BMI, body fat and leptin and inversely with age in the combined group including IGT and T2DM patients but not in the group without IGT

and T2DM patients. On the contrary, plasma clusterin correlated positively with fasting insulin only in the combined group without IGT and T2DM patients.

In both combined groups (with or without T2DM patients) mRNA clusterin correlated positively with BMI, body fat, waist circumference, serum triglycerides, fasting insulin, HOMA index, CRP, leptin and leptin mRNA in SCAT.

We could not find a correlation between plasma clusterin and plasma leptin or between plasma clusterin and mRNA clusterin in SCAT.

According to the multiple linear regression model, none of the parameters included was an independent predictor of plasma clusterin levels in a combined group without T2DM and IGT patients. Plasma clusterin levels in the combined group of all patients, including T2DM and IGT, could be predicted only from one independent variable - age with $p=0.004$ and the adjusted $R^2 = 0.099$. The clusterin mRNA levels in both combined groups could be predicted from a linear combination of two independent variables: leptin mRNA expression ($p<0.001$) and waist circumference ($p<0.001$) – the adjusted R^2 was 0.645 for the group without T2DM and IGT and 0.598 for the group of all patients.

DISCUSSION

We have identified clusterin by low density Protein Array as one of the proteins being markedly increased in the adipose tissue of obese patients suggesting that it may also have a local regulatory role in adipose tissue and its metabolic changes in obesity. To this end, we measured its mRNA expression and plasma concentrations in obese patients with and without type 2 diabetes mellitus and explored its modulation by different interventions to gain further insight into its possible regulatory role in the adipose tissue.

In our study, we found no significant differences in circulating clusterin levels between controls, obese and T2DM patients what would indicate that clusterin does not have a systemic role in the etiopathogenesis of metabolic complications of obesity. Our results are in agreement with those of Poulakou and colleagues (Poulakou *et al.* 2008) who found similar levels of plasma clusterin in diabetic and non-diabetic patients with the same BMI and also with those of Arnold and colleagues (Arnold *et al.* 2011) who did not find any difference between obese and normal weight adolescents. On the contrary, other studies found increased plasma clusterin levels in obese and T2DM patients (Trougakos *et al.* 2002, Won *et al.* 2014).

In our previous studies, we have demonstrated the beneficial effect of various weight reduction methods on the metabolic and proinflammatory profile of obese patients both with and without type 2 diabetes mellitus (Mraz *et al.* 2011, Touskova *et al.* 2012, Urbanova *et al.* 2014). In this study, we investigated whether very-low-calorie diet (VLCD) and laparoscopic sleeve gastrectomy (LSG) affect plasma clusterin concentrations or its mRNA expression in subcutaneous adipose tissue in obese patients with or without T2DM. We found a marked decrease in plasma clusterin after 2 weeks of VLCD in obese but interestingly not in T2DM patients. The reason for this differential response is not clear. One of the possible explanations could be the fact that metabolic derangements in patients with obesity and type 2 diabetes are more profound and a shorter intervention with very-low-calorie diet was not sufficient enough to induce complete systemic changes (Galgani *et al.* 2008). Alternatively, considering the similar direction of difference and comparable post-interventional plasma clusterin levels in both groups, the absence of a clear effect of VLCD in T2DM subjects could be the result of a relatively small number of patients in the group. Nevertheless, the lack of changes in plasma clusterin concentrations after LSG argues against its direct regulation by weight reducing interventions or against its significant role in the modulation of energy homeostasis.

Along the same lines, we were not able to find any correlation between plasma clusterin and BMI, body fat or waist circumference in the combined group of patients without IGT and T2DM. This is in agreement with some of the previous studies (Arnold *et al.* 2011, Kujiraoka *et al.* 2006, Poulakou *et al.* 2008) which also did not find any relationship between circulating clusterin and BMI. In our study, we also examined sex-dependent differences in plasma clusterin levels. The study by Poulakou and colleagues (Poulakou *et al.* 2008) showed higher levels of clusterin in male compared with female subjects. In our study we did not find any gender differences, which could have been due to the relatively low number of subjects included or their different characteristics as compared to Poulakou's study.

According to the available data, about 40-60 % of clusterin in circulating blood is supposed to be part of the HDL particle, where it is bound to apolipoprotein-A1 (James *et al.* 1991, Jenne *et al.* 1991). It also could be part of the low density lipoprotein (LDL) (Hoofnagle *et al.* 2010, Pettersson *et al.* 2011). There is a strong inverse relationship between the amount of clusterin in HDL and in LDL/VLDL (Hoofnagle *et al.* 2010). With respect to these data it is interesting to note, that we did not find any correlation between plasma clusterin and HDL or LDL cholesterol. Clusterin probably also creates complexes with leptin and acts as a regulator of leptin activity, although the importance of this mechanism is controversial (Arnold *et al.* 2011, Bajari *et al.* 2003). In our study, we found only a weak correlation of plasma clusterin with plasma leptin in the combined group of all patients and no correlation in the group without IGT and T2DM subjects. This result is in accordance with the results of Arnold and colleagues (Arnold *et al.* 2011) who also did not find any such relationship.

To our best knowledge, no information regarding the clusterin mRNA expression in adipose tissue is currently available. In our study, clusterin mRNA expression in SCAT was increased compared with control group in both OB and T2DM groups and remained increased after 2 weeks of VLCD. On the contrary, 6 months after LSG clusterin mRNA expression was

decreased by 30 % compared with baseline and remained lower by 23 % even 12 months after LSG. In other tissues, clusterin was identified as the gene whose increased expression could indicate the repair or remodeling of damaged tissue (Hoofnagle *et al.* 2010, Jenne *et al.* 1991). One of the consequences of obesity is increased rate of apoptosis and cell death in adipose tissue. *In vivo*, clusterin expression appears to be associated with cell survival (Humphreys *et al.* 1999). It is therefore tempting to speculate that increased mRNA expression of clusterin in adipose tissue in obese patients could be the marker of a compensatory mechanism protecting the tissue against apoptosis as a result of weight-reducing interventions. This possibility is also supported by the fact that in the multiple linear regression model clusterin mRNA expression in SCAT could be predicted from leptin mRNA expression together with waist circumference.

One of the proposed roles of clusterin bound with HDL cholesterol is its beneficial influence on atherosclerosis, since the lack of clusterin in HDL particles impairs the lipoprotein's cardioprotective functions (Hoofnagle *et al.* 2010, James *et al.* 1991). Increased amount of clusterin was found in arterial wall during the development of atherosclerosis (Trougakos *et al.* 2002). Clusterin in the HDL complex probably serves as a regulator of lipid transport and local lipid redistribution but not as the molecule transporting lipids itself (Jenne *et al.* 1991, Trougakos *et al.* 2002).

One of the primary actions of clusterin could be the repression of inflammation (Kounnas *et al.* 1995), although the evidence in support of this idea is not clear. According to the study of Shim and colleagues (Shim *et al.* 2012) clusterin upregulates expression of chemotactic cytokines as e.g. monocyte chemoattractant protein-1 and induces the migration of macrophages both directly and by the induction of TNF- α . On the other hand, clusterin was found to reduce the expression of TNF- α *in vivo* and clusterin-deficient mice showed enhanced infiltration of inflammatory cells during pancreatitis (Savkovic *et al.* 2007). Moreover, clusterin

overexpression attenuates the expression of proinflammatory chemokines (Kim *et al.* 2009) and in the model of clusterin deficient mice it limits the progression of autoimmune myocarditis and protects the heart from postinflammatory tissue destruction (McLaughlin *et al.* 2000). Thus we could hypothesize that clusterin might have an anti-inflammatory function also in adipose tissue, which role could be another explanation for its elevated mRNA expression in subcutaneous adipose tissue of obese patients that is typically characterized by chronic low-grade inflammation. This idea is also supported by the fact that in our study clusterin mRNA expression in SCAT of both combined groups with or without T2DM patients correlated positively not only with markers of obesity (BMI, body fat, waist circumference) but also with serum triglycerides, fasting insulin, HOMA index and the inflammatory marker CRP. Chronic low-grade inflammation in obese subject is one of the mechanisms contributing to the development of atherosclerosis and thus the anti-inflammatory effect of clusterin could also be protection against atherosclerosis. On the contrary, the fact that ApoE-KO mice with decreased expression of nuclear clusterin have reduced atherosclerotic lesions argues against its antiatherosclerotic role (Hamada *et al.* 2011).

While a strong positive correlation between clusterin levels in HDL particles and insulin sensitivity was found in humans (Hoofnagle *et al.* 2010), little is known about the acute regulatory role of insulin and glucose in the changes of clusterin mRNA expression. In the primary hepatocytes and hepatoma cell lines, high glucose concentrations increased clusterin expression (Kim *et al.* 2011). To assess the effect of insulin and glucose levels on plasma levels and mRNA expression of clusterin in SCAT, we performed a hyperinsulinemic euglycemic clamp (HEC). We could not find any significant changes in plasma clusterin levels during HEC in any of the studied groups or any relationship between plasma clusterin area under the curve or its mRNA expression and insulin sensitivity index. mRNA expression

of clusterin was elevated at the end of HEC compared with baseline only in the normoglycemic group, but not in the IGT or T2DM group. The explanation of this phenomenon remains unclear and warrants further investigations.

In summary, plasma clusterin concentrations did not differ between healthy subjects and obese patients with or without type 2 diabetes mellitus and they were only partially influenced by short-term weight reduction. On the contrary, clusterin mRNA expression in subcutaneous fat was higher in obese and T2DM patients compared with lean controls and it decreased after bariatric surgery but not after short-term caloric restriction. Clusterin mRNA correlated positively with markers of obesity, serum triglycerides, fasting insulin, HOMA index and the inflammatory marker CRP. Taken together, our data suggest a possible local regulatory role for clusterin in the adipose tissue rather than its systemic involvement in the regulation of energy homeostasis.

Acknowledgements

Supported by RVO VFN64165, SVV260145/2015 and OPPK project CZ.2.16/3.1.00/24012.

Reference list

ARNOLD T, BRANDLHOFFER S, VRTIKAPA K, STANGL H, HERMANN M, ZWIAUER K, MANGGE H, KARWAUTZ A, HUEMER J, KOLLER D, SCHNEIDER W J, STROBL W: Effect of obesity on plasma clusterin, [corrected] a proposed modulator of leptin action. *Pediatr Res* **69**(3): 237-242, 2011.

ARONOW B J, LUND S D, BROWN T L, HARMONY J A, WITTE D P: Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. *Proc Natl Acad Sci U S A* **90**(2): 725-729, 1993.

BAJARI T M, STRASSER V, NIMPF J, SCHNEIDER W J: A model for modulation of leptin activity by association with clusterin. *FASEB J* **17**(11): 1505-1507, 2003.

BLASCHUK O, BURDZY K, FRITZ I B: Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. *J Biol Chem* **258**(12): 7714-7720, 1983.

FRIED M, YUMUK V, OPPERT J M, SCOPINARO N, TORRES A J, WEINER R, YASHKOV Y, FRUHBECK G, EUROPEAN ASSOCIATION FOR THE STUDY OF O, INTERNATIONAL FEDERATION FOR THE SURGERY OF OBESITY - EUROPEAN C: Interdisciplinary European Guidelines on metabolic and bariatric surgery. *Obes Facts* **6**(5): 449-468, 2013.

FRITZ I B, BURDZY K, SETCHELL B, BLASCHUK O: Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. *Biol Reprod* **28**(5): 1173-1188, 1983.

GALGANI J E, HEILBRONN L K, AZUMA K, KELLEY D E, ALBU J B, PI-SUNYER X, SMITH S R, RAVUSSIN E, LOOK A A R G: Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate. *Diabetes* **57**(4): 841-845, 2008.

HAMADA N, MIYATA M, ETO H, IKEDA Y, SHIRASAWA T, AKASAKI Y, MIYAUCHI T, FURUSHO Y, NAGAKI A, ARONOW B J, TEI C: Loss of clusterin limits atherosclerosis in apolipoprotein E-deficient mice via reduced expression of Egr-1 and TNF-alpha. *J Atheroscler Thromb* **18**(3): 209-216, 2011.

HOOFNAGLE A N, WU M, GOSMANOVA A K, BECKER J O, WIJSMAN E M, BRUNZELL J D, KAHN S E, KNOPP R H, LYONS T J, HEINECKE J W: Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. *Arterioscler Thromb Vasc Biol* **30**(12): 2528-2534, 2010.

HUMPHREYS D T, CARVER J A, EASTERBROOK-SMITH S B, WILSON M R: Clusterin has chaperone-like activity similar to that of small heat shock proteins. *J Biol Chem* **274**(11): 6875-6881, 1999.

CHOI-MIURA N H, IHARA Y, FUKUCHI K, TAKEDA M, NAKANO Y, TOBE T, TOMITA M: SP-40,40 is a constituent of Alzheimer's amyloid. *Acta Neuropathol* **83**(3): 260-264, 1992.

JAMES R W, HOCHSTRASSER A C, BORGHINI I, MARTIN B, POMETTA D, HOCHSTRASSER D: Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. *Arterioscler Thromb* **11**(3): 645-652, 1991.

JENNE D E, LOWIN B, PEITSCH M C, BOTTCHER A, SCHMITZ G, TSCHOPP J: Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. *J Biol Chem* **266**(17): 11030-11036, 1991.

KIM G, KIM G H, OH G S, YOON J, KIM H W, KIM M S, KIM S W: SREBP-1c regulates glucose-stimulated hepatic clusterin expression. *Biochem Biophys Res Commun* **408**(4): 720-725, 2011.

KIM H J, YOO E K, KIM J Y, CHOI Y K, LEE H J, KIM J K, JEOUNG N H, LEE K U, PARK I S, MIN B H, PARK K G, LEE C H, ARONOW B J, SATA M, LEE I K: Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. *Arterioscler Thromb Vasc Biol* **29**(10): 1558-1564, 2009.

KOUNNAS M Z, LOUKINOVA E B, STEFANSSON S, HARMONY J A, BREWER B H, STRICKLAND D K, ARGRAVES W S: Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. *J Biol Chem* **270**(22): 13070-13075, 1995.

KUJIRAOKA T, HATTORI H, MIWA Y, ISHIHARA M, UENO T, ISHII J, TSUJI M, IWASAKI T, SASAGURI Y, FUJIOKA T, SAITO S, TSUSHIMA M, MARUYAMA T, MILLER I P, MILLER N E, EGASHIRA T: Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. *J Atheroscler Thromb* **13**(6): 314-322, 2006.

MCLAUGHLIN L, ZHU G, MISTRY M, LEY-EBERT C, STUART W D, FLORIO C J, GROEN P A, WITT S A, KIMBALL T R, WITTE D P, HARMONY J A, ARONOW B J: Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. *J Clin Invest* **106**(9): 1105-1113, 2000.

MRAZ M, LACINOVA Z, DRAPALOVA J, HALUZIKOVA D, HORINEK A, MATOULEK M, TRACHTA P, KAVALKOVA P, SVACINA S, HALUZIK M: The effect of very-low-calorie diet on mRNA expression of inflammation-related genes in subcutaneous adipose tissue and peripheral monocytes of obese patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab* **96**(4): E606-613, 2011.

OBERBACH A, BLUHER M, WIRTH H, TILL H, KOVACS P, KULLNICK Y, SCHLICHTING N, TOMM J M, ROLLE-KAMPCZYK U, MURUGAIYAN J, BINDER H, DIETRICH A, VON BERGEN M: Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. *J Proteome Res* **10**(10): 4769-4788, 2011.

PETTERSSON C, KARLSSON H, STAHLMAN M, LARSSON T, FAGERBERG B, LINDAHL M, WIKLUND O, BOREN J, FOGELSTRAND L: LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome. *J Intern Med* **269**(3): 306-321, 2011.

POULAKOU M V, PARASKEVAS K I, WILSON M R, ILIOPOULOS D C, TSIGRIS C, MIKHAILIDIS D P, PERREA D: Apolipoprotein J and leptin levels in patients with coronary heart disease. *In Vivo* **22**(4): 537-542, 2008.

SAVKOVIC V, GANTZER H, REISER U, SELIG L, GAISER S, SACK U, KLOPPPEL G, MOSSNER J, KEIM V, HORN F, BODEKER H: Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. *Biochem Biophys Res Commun* **356**(2): 431-437, 2007.

SHIM Y J, KANG B H, CHOI B K, PARK I S, MIN B H: Clusterin induces the secretion of TNF-alpha and the chemotactic migration of macrophages. *Biochem Biophys Res Commun* **422**(1): 200-205, 2012.

SONG F, POLJAK A, CRAWFORD J, KOCHAN N A, WEN W, CAMERON B, LUX O, BRODATY H, MATHER K, SMYTHE G A, SACHDEV P S: Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. *PLoS One* **7**(6): e34078, 2012.

TOUSKOVA V, TRACHTA P, KAVALKOVA P, DRAPALOVA J, HALUZIKOVA D, MRAZ M, LACINOVA Z, MAREK J, HALUZIK M: Serum concentrations and tissue expression of components of insulin-like growth factor-axis in females with type 2 diabetes mellitus and obesity: the influence of very-low-calorie diet. *Mol Cell Endocrinol* **361**(1-2): 172-178, 2012.

TROUGAKOS I P, POULAKOU M, STATHATOS M, CHALIKIA A, MELIDONIS A, GONOS E S: Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. *Exp Gerontol* **37**(10-11): 1175-1187, 2002.

URBANOVA M, DOSTALOVA I, TRACHTA P, DRAPALOVA J, KAVALKOVA P, HALUZIKOVA D, MATOULEK M, LACINOVA Z, MRAZ M, KASALICKY M, HALUZIK M: Serum concentrations and subcutaneous adipose tissue mRNA expression of omentin in morbid obesity and type 2 diabetes mellitus: the effect of very-low-calorie diet, physical activity and laparoscopic sleeve gastrectomy. *Physiol Res* **63**(2): 207-218, 2014.

WON J C, PARK C Y, OH S W, LEE E S, YOUN B S, KIM M S: Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. *PLoS One* **9**(7): e103351, 2014.

ZERRAD-SAADY A, THEROND P, CHANTEPIE S, COUTURIER M, RYE K A, CHAPMAN M J, KONTUSH A: HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. *Arterioscler Thromb Vasc Biol* **29**(12): 2169-2175, 2009.




Figure 1. Difference in amount of clusterin in the sample of Control and Obese patient on the low density Protein Array

C - control subject; OB - obese woman without type 2 diabetes mellitus

Table 1. Clinical, hormonal and metabolic characteristics of the Control group and Obese and T2DM patients before and after 2 weeks of VLCD.

	Control	OB before VLCD	OB after VLCD	T2DM before VLCD	T2DM after VLCD
No. of subjects (female/male)	15 (15/0)	15 (15/0)	11 (11/0)	15 (15/0)	15 (15/0)
Age (years)	49.3 ± 1.7	50.2 ± 2.6	X	55.8 ± 1.6	X
BMI (kg/m ²)	23.9 ± 0.6	51.6 ± 2.5^C	49.4 ± 2.5^{CB}	52.0 ± 2.6^C	49.4 ± 2.4^{CB}
Body fat (kg)	20.8 ± 1.6	80.0 ± 6.4^C	74.8 ± 6.1^{CB}	74.3 ± 5.7^C	69.5 ± 5.0^{CB}
Waist circumference (cm)	79.0 ± 2.4	131.6 ± 4.1^C	127.8 ± 4.3^{CB}	135 ± 4.5^C	130.1 ± 4.4^{CB}
Fasting blood glucose (mmol/l)	4.82 ± 0.09	5.19 ± 0.26	4.69 ± 0.14	9.65 ± 1.09^{CO}	7.84 ± 0.66^{CO}
Glycated hemoglobin (% IFCC)	3.78 ± 0.08	4.27 ± 0.16	X	7.77 ± 0.69^{CO}	X
Total cholesterol (mmol/l)	5.39 ± 0.28	5.26 ± 0.40	4.21 ± 0.39^{CB}	4.77 ± 0.37	3.77 ± 0.22^{CB}
HDL cholesterol (mmol/l)	1.58 ± 0.07	1.37 ± 0.11	1.17 ± 0.14^{CB}	1.12 ± 0.06^C	0.95 ± 0.04^{CB}
LDL cholesterol (mmol/l)	3.31 ± 0.21	3.14 ± 0.29	2.49 ± 0.29^C	2.72 ± 0.31	1.99 ± 0.20^{CB}
Triglycerides (mmol/l)	1.10 ± 0.16	1.66 ± 0.27	1.23 ± 0.22	2.22 ± 0.34^C	1.86 ± 0.19^{CO}
Fasting insulin (μIU/ml)	15.8 ± 0.7	43.6 ± 7.4^C	34.9 ± 5.1^C	53.6 ± 11.3^C	44.3 ± 4.7^C
HOMA-IR index	3.39 ± 0.18	11.01 ± 2.40^C	7.97 ± 1.39	22.93 ± 4.70^{CO}	14.27 ± 1.40^{CO}
CRP (mg/l)	0.194 ± 0.056	2.141 ± 0.550^C	1.911 ± 0.584^{CB}	2.497 ± 0.361^C	1.775 ± 0.294^C
Serum leptin (ng/ml)	14.3 ± 2.1	57.1 ± 6.6^C	45.9 ± 8.1^{CB}	58.6 ± 5.1^C	54.8 ± 6.1^C
Plasma clusterin (μg/ml)	77.2 ± 7.7	70.0 ± 3.9	60.3 ± 5.2^B	63.8 ± 2.8	60.4 ± 2.3
mRNA clusterin	1.103 ± 0.118	1.894 ± 0.197^C	1.676 ± 0.136^C	2.046 ± 0.118^C	1.888 ± 0.206^C
mRNA leptin	1.144 ± 0.136	1.549 ± 0.216	1.655 ± 0.177	1.562 ± 0.216	1.635 ± 0.191

Control - control group of healthy women; OB - obese women without type 2 diabetes mellitus; T2DM - obese women with type 2 diabetes mellitus.

Values are means ± SEM. Statistical significance is from One way ANOVA vs. control group, One Way RM ANOVA and paired t-test (see part Statistical Analysis) or its nonparametric versions, as appropriate. ^C p < 0.05 vs. control group; ^O p < 0.05 vs. obese patients, ^B p < 0.05 vs. before VLCD

Table 2. Anthropometric, biochemical and hormonal characteristics of control group and obese non-diabetic subjects before, 6 months and 12 months after laparoscopic sleeve gastrectomy

	Control	Obese before LSG	Obese 6months after LSG	Obese 12m after LSG
No. of subjects (female/male)	15 (15/0)	10 (10/0)	10 (10/0)	10 (10/0)
Age (years)	49.3 ± 1.7	40.6 ± 2.6^C	X	X
BMI (kg/m ²)	23.9 ± 0.6	43.3 ± 2.7^C	33.4 ± 1.9^{CB}	32.9 ± 2.5^{CB}
Body fat (kg)	20.8 ± 1.6	60.5 ± 7.2^C	39.4 ± 4.5^{CB}	38.8 ± 5.9^{CB}
Waist circumference (cm)	79 ± 2.4	118.4 ± 4.6^C	98.1 ± 3.7^{CB}	97.1 ± 5.2^{CB}
Fasting blood glucose (mmol/l)	4.82 ± 0.09	4.97 ± 0.22	4.82 ± 0.13	4.86 ± 0.12
Glycated hemoglobin (% IFCC)	3.78 ± 0.08	3.91 ± 0.22	3.83 ± 0.16	3.60 ± 0.12
Total cholesterol (mmol/l)	5.39 ± 0.28	5.22 ± 0.31	5.12 ± 0.33	5.04 ± 0.49
HDL cholesterol (mmol/l)	1.58 ± 0.07	1.26 ± 0.13^C	1.37 ± 0.13^C	1.53 ± 0.19^B
LDL cholesterol (mmol/l)	3.31 ± 0.21	3.33 ± 0.30	3.16 ± 0.28	3.10 ± 0.37
Triglycerides (mmol/l)	1.10 ± 0.16	1.53 ± 0.15	1.31 ± 0.12	1.10 ± 0.12^B
Fasting insulin (μIU/ml)	15.8 ± 0.7	31.6 ± 5.3^C	23.2 ± 3.3	23.1 ± 4.3
HOMA-IR index	3.39 ± 0.18	7.25 ± 1.50^C	5.01 ± 0.72	4.94 ± 0.80
CRP (mg/l)	0.194 ± 0.056	0.923 ± 0.162^C	0.613 ± 0.126^{CB}	0.499 ± 0.168^{BA}
Serum leptin (ng/ml)	14.3 ± 2.1	56.3 ± 9.6^C	25.6 ± 7.7^B	32.5 ± 11.3^B
Plasma clusterin (μg/ml)	77.2 ± 7.7	75.6 ± 7.3	71.8 ± 6.6	71.4 ± 5.7
mRNA clusterin	1.103 ± 0.118	2.771 ± 0.288^C	1.930 ± 0.222^{CB}	2.145 ± 0.294^{CB}
mRNA leptin	1.144 ± 0.136	2.233 ± 0.298^C	1.451 ± 0.16	1.837 ± 0.185^C

Values are means ± SEM. Statistical significance is from One way ANOVA vs. control group, One Way RM ANOVA and paired t-test (see part Statistical Analysis) or its nonparametric versions, as appropriate. ^C p< 0.05 vs. control group; ^B p< 0.05 vs. obese patient before LSG; ^A p< 0.05 vs. obese patient 6 months after LSG

Table 3. Clinical, hormonal and metabolic characteristics of the patients who underwent euglycemic hyperinsulinemic clamp.

	NGT	IGT	T2DM
No. of subjects (female/male)	8 (4/4)	8 (4/4)	8 (4/4)
Age (years)	55.0 ± 1.5	60.1 ± 1.8^N	60.8 ± 1.1^N
BMI (kg/m ²)	28.6 ± 1.4	29.8 ± 1.0	29.7 ± 1.3
Body fat (kg)	25.1 ± 4.1	27.3 ± 2.9	30.3 ± 3.2
Waist circumference (cm)	91.1 ± 4.5	99.8 ± 2.6	102.8 ± 3.1
Fasting blood glucose (mmol/l)	4.91 ± 0.17	5.92 ± 0.24^N	7.08 ± 0.36^{NI}
Glycated haemoglobin (% IFCC)	4.06 ± 0.13	4.31 ± 0.10	4.79 ± 0.14^N
Total cholesterol (mmol/l)	5.30 ± 0.31	5.62 ± 0.36	4.42 ± 0.27^I
HDL cholesterol (mmol/l)	1.64 ± 0.15	1.57 ± 0.10	1.12 ± 0.12^{NI}
LDL cholesterol (mmol/l)	3.22 ± 0.19	3.33 ± 0.28	2.61 ± 0.12
Triglycerides (mmol/l)	0.99 ± 0.08	2.01 ± 0.56	2.20 ± 0.56
Fasting insulin (μIU/ml)	13.4 ± 1.7	27.2 ± 4.8	31.3 ± 7.1
HOMA-IR index	2.97 ± 0.48	6.84 ± 0.88^N	9.34 ± 2.66^N
CRP (mg/l)	0.690 ± 0.337	1.148 ± 0.265	1.212 ± 0.523
Insulin Sensitivity Index (ml*kg ⁻¹ *min ⁻¹ *μIU ⁻¹ *ml ⁻¹)	0.022 ± 0.003	0.015 ± 0.002	0.009 ± 0.002^N
Serum leptin (ng/ml)	9.7 ± 2.8	16.0 ± 5.1	33.1 ± 8.2
Basal plasma clusterin (μg/ml)	41.1 ± 3.0	54.0 ± 2.9	53.9 ± 5.8
mRNA leptin – before HEC	1.554 ± 0.277	1.167 ± 0.142	1.420 ± 0.188
mRNA leptin – after HEC	1.799 ± 0.247	1.649 ± 0.231^B	1.705 ± 0.201
mRNA clusterin – before HEC	1.760 ± 0.200	1.591 ± 0.136	1.696 ± 0.141
mRNA clusterin – after HEC	2.041 ± 0.256^B	1.845 ± 0.224	1.921 ± 0.164

NGT - normoglycemic group; IGT - group with impaired glucose tolerance; T2DM - group with type 2 diabetes mellitus.

Values are means ± SEM. Statistical significance is from paired t test and One way ANOVA or its nonparametric version, as appropriate. ^N p< 0.05 vs. NGT; ^I p< 0.05 vs. IGT, ^B p< 0.05 vs. before HEC.

Table 4. The relationship of serum clusterin levels and its mRNA expression in SCAT to other studied parameters.

	Plasma clusterin ($\mu\text{g/ml}$)				mRNA clusterin			
	C+NGT+OB		C+NGT+OB+IGT+T2DM		C+NGT+OB		C+NGT+OB+IGT+T2DM	
	R	p	R	p	R	p	R	p
Age (years)	-0.200	0.167	-0.287	0.010	-0.263	0.063	-0.193	0.086
BMI (kg/m^2)	0.147	0.314	0.254	0.023	0.455	<0.001	0.473	<0.001
Body fat (kg)	0.228	0.114	0.284	0.011	0.444	0.001	0.466	<0.001
Waist circumference (cm)	0.155	0.287	0.216	0.054	0.452	<0.001	0.468	<0.001
Fasting blood glucose (mmol/l)	0.131	0.369	-0.103	0.363	0.136	0.341	0.121	0.283
Glycated haemoglobin (% IFCC)	-0.073	0.624	-0.092	0.422	0.063	0.670	0.161	0.161
Total cholesterol (mmol/l)	0.133	0.361	0.178	0.117	0.036	0.804	0.006	0.957
HDL cholesterol (mmol/l)	-0.123	0.402	-0.008	0.948	-0.274	0.054	-0.220	0.053
LDL cholesterol (mmol/l)	0.076	0.608	0.149	0.198	-0.008	0.954	-0.010	0.931
Triglycerides (mmol/l)	0.221	0.126	0.150	0.187	0.445	0.001	0.375	<0.001
Fasting insulin ($\mu\text{IU/ml}$)	0.313	0.046	0.237	0.055	0.515	<0.001	0.443	<0.001
HOMA-IR index	0.303	0.054	0.159	0.203	0.491	<0.001	0.401	<0.001
CRP (mg/l)	0.117	0.441	0.090	0.453	0.410	0.004	0.273	0.021
Leptin (ng/ml)	0.224	0.138	0.268	0.023	0.561	<0.001	0.543	<0.001
Plasma clusterin ($\mu\text{g/ml}$)	X	X	X	X	-0.039	0.798	0.040	0.735
mRNA leptin	-0.133	0.388	0.031	0.796	0.743	<0.001	0.684	<0.001

C - lean controls; NGT - normoglycemic group; OB - obese patients without T2DM; IGT - impaired glucose tolerance group, T2DM - group with type 2 diabetes mellitus. C+NGT+OB+IGT+T2DM: n= 80; C+NGT+OB: n = 51. Values are means \pm SEM. Statistical significance is from Spearman Rank Order Correlation test. $p < 0.05$ was assed as statistical significant